Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 16/20 | 1.00 |
| ▸ | BRD4 | O60885 | 4/20 | 0.55 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.55 |
| ▸ | PRKCI | P41743 | 1/20 | 0.53 |
| ▸ | BRD1 | O95696 | 8/20 | 0.47 |
| ▸ | BRPF3 | Q9ULD4 | 3/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11743970 | 0.86 | BRPF1 (0.76) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL422084 | 0.78 | BRPF1 (0.65) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL17505180 | 0.78 | BRPF1 (0.63) | BRPF1PRKCICHEK1AURKADAPK3 | |
| SCHEMBL29213971 | 0.77 | BRPF1 (0.62) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL2172818 | 0.77 | BRPF1 (0.62) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL31202712 | 0.77 | BRPF1 (0.62) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL8556776 | 0.77 | BRPF1 (0.62) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL9257087 | 0.77 | BRPF1 (0.62) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL1771879 | 0.77 | BRPF1 (0.62) | BRPF1BRD4BRD9CA12CA9 | |
| SCHEMBL1238373 | 0.77 | BRPF1 (0.62) | BRPF1BRD4BRD9CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590066-B2 | Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-4272832-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2023-09-21 | — | — | US | disclosed |
| EP-4169905-A1 | NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2023-04-26 | — | — | EP | disclosed |
| CN-115867277-A | Novel fused heterocyclyl-carbohydrazone acyldinitrile compounds and use thereof | 韩国科学技术研究院 | 2023-03-28 | — | — | CN | disclosed |
| WO-2021256899-A1 | NOVEL FUSED HETEROCYCLIC CARBONOHYDRAZONOYL DICYANIDE COMPOUND AND USE THEREOF | 한국과학기술연구원 | 2021-12-23 | — | — | WO | disclosed |
| US-20210139522-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| EP-2699579-A1 | PYRAZOLO [4, 3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | Origenis GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012143144-A1 | PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| EP-1276726-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | BRPF1 2837/4885BRD4 2023/4885BRD9 2148/4885 |
| US-20210139522-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CFTR, ABCB11, CEL | BRPF1 2281/4885BRD4 4754/4885BRD9 3965/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | BRPF1 2950/4885BRD4 1732/4885BRD9 1873/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | BRPF1 2837/4885BRD4 2023/4885BRD9 2148/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | BRPF1 2837/4885BRD4 2023/4885BRD9 2148/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | BRPF1 3000/4885BRD4 1571/4885BRD9 2023/4885 |
| US-12590066-B2 | Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CLIC1 | BRPF1 4446/4885BRD4 1172/4885BRD9 2636/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | BRPF1 2740/4885BRD4 1774/4885BRD9 1903/4885 |
| US-20230295095-A1 | NOVEL FUSED-HETEROCYCLYL-CARBONOHYDRAZONOYL DICYANIDE COMPOUNDS AND USE THEREOF | CBR3, DBF4, DDT | BRPF1 3211/4885BRD4 260/4885BRD9 1441/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | BRPF1 2740/4885BRD4 1774/4885BRD9 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.